Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 6/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384879 | 0.84 | ERN1 (0.44) | ERN1ALOX15ALOX12APPALOX5 | |
| SCHEMBL6541836 | 0.80 | ERN1 (0.60) | ERN1ALOX15ALOX12APPALOX5 | |
| SCHEMBL21614381 | 0.79 | ESR1 (0.40) | ERN1ALOX15ALOX12APPALOX5 | |
| SCHEMBL11142895 | 0.78 | ERN1 (0.48) | ERN1ALOX15ALOX12APPALOX5 | |
| SCHEMBL10943574 | 0.78 | HPGD (0.50) | ERN1ALOX15ALOX12APPMAOB | |
| SCHEMBL19701751 | 0.78 | ERN1 (0.40) | ERN1ALOX15ALOX12APPGAA | |
| SCHEMBL524860 | 0.77 | NQO2 (0.44) | ERN1ALOX15ALOX12APPGAA | |
| SCHEMBL10935658 | 0.77 | ACHE (0.48) | ERN1ALOX12MAOBGAAALDH1A1 | |
| SCHEMBL30927163 | 0.77 | ALOX15 (0.56) | ERN1ALOX15ALOX12APPALOX5 | |
| SCHEMBL129971 | 0.77 | ALOX15 (0.56) | ERN1ALOX15ALOX12APPALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3285760-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | Omeros Corporation (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9879002-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879002-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170022190-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-01-26 | — | — | US | disclosed |
| US-20170022190-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-01-26 | — | — | US | disclosed |
| WO-2016172573-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016172573-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022190-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | ERN1 4596/4885ALOX15 2068/4885ALOX12 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.